NCT07783477|RecruitingPhase 1DMCFDA Drug
A Study of Armored CAR T Cells in People With Cancer
A Phase I Trial for R/R MetAstatic DLL3+ Cancers Utilizing Armored CAR T Cells (ARMADA)
Loading search results
Sponsor study identifier
Secondary identifiers
interventional
16
1 country
7
Study Start
August 28, 2026
Actual (reported)Primary Completion
August 28, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 28, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 28, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 20, 2026
Actual (reported)August 24, 2026
Actual (reported)August 28, 2026
Actual (reported)August 28, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 28, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Maximum Tolerated Dose/MTD of DLL3-SAVVYZ-IL18 CAR T cell
The objective of the dose-escalation phase is to determine the MTD of this dose-escalation schedule. The MTD will be defined as the dose at which the toxicity rate does not exceed an acceptable threshold of toxicity, assumed at 25% in this study.
up to 1 year
This is the starting dose of DLL3-SAVVYZ-IL18 CAR T cell Dose
Eligible participants will receive DLL3-SAVVYZ-IL18 CAR T cell Dose at this Dose Level if no Dose Limiting Toxicities are experienced at Dose Level 1
Eligible participants will receive DLL3-SAVVYZ-IL18 CAR T cell Dose at this Dose Level if Dose Limiting Toxicities are experienced at Dose Level 1
DLL3-SAVVYZ-IL18 CAR T cell
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
Adam Schoenfeld, MD
Memorial Sloan Kettering Cancer Center
First Submitted
August 20, 2026
First Posted
August 24, 2026
Study Start
August 28, 2026
Actual (reported)Primary Completion
August 28, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
Study Completion
August 28, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 22, 2026
Record last verified: 2026-10
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: